Openbookopenbook
Equity
Alcon AG(ALC)
USD --+0.00%
Reward61Moderate
Risk27Low
📊75%Data
ALC
+0.0 · +0.00%
USD · NYSE
Alcon AG | Healthcare
Defensive Anchor
Market Cap:36.39Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
27
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ALC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $94.68.

What is Alcon AG?

researches, develops, manufactures, distributes, and sells eye care products worldwide.

ALC · Verdict

Solid reward · low risk

ALC scores well on cash flow and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

ALC · Verdict

What’s working & what to watch

Strengths 5

  • Cash flow81/100

    17% free-cash-flow margin

  • Balance sheet71/100

    Interest covered 5.7×

  • Profitability68/100

    9% net margin · 5% ROE

  • Growth65/100

    Rev +6.1% CAGR · earnings +43.0%

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Alcon AG?

researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 36.39B, and a P/E ratio of 36.8x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap36.39B
P/E Ratio36.7727
Dividend Yield0.48%
52 Week High98.8453
52 Week Low71.55
Last AnnualDecember
IPO Date4/9/2019
IncorporatedUSA
Shares Outstanding487M
No. of Employees25,942
IndustryMedical Instruments & Supplies
ExchangeNYSE
Beta0.737
CurrencyUSD
Websitewww.alcon.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.